Memorial Sloan Kettering Medical Oncologist Komal Jhaveri

Komal Jhaveri, MD, FACP

Medical Oncologist

Titles

Section Head, Endocrine Therapy Research Program; Clinical Director, Early Drug Development Service

Clinical Expertise

Breast Cancer; Early-Phase Clinical Trials

Share

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Monday through Friday, 8:00 a.m. to 6:00 p.m., (Eastern time)
Accepted Insurance Providers

Dr. Jhaveri accepts the following list of insurance providers. Select your insurance provider to see more details.

Aetna

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (City of NY retirees only, starting 7/1/23)

Payor Type:
In Network Coverage Type(s): PPO

Blue Cross Blue Shield Federal Employee Program

Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO

Blue Cross Blue Shield New York

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS

Blue Cross Health Plus

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Carrum Health

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

Cigna

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Connecticare

Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO

Emblem

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Emblem Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Emblem Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Empire Blue Cross Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO, DSN

Empire Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Fidelis

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO

Fidelis Managed Medicaid & HARP

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Fidelis Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO

First Health

Payor Type:
In Network Coverage Type(s): PPO

Healthfirst

Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Healthfirst Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO, PPO

Healthsmart

Payor Type: Commercial
In Network Coverage Type(s): PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

Payor Type: Commercial
In Network Coverage Type(s): HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Husky CT Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Magnacare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO

Medicare Part A&B (traditional Medicare)

Payor Type:
In Network Coverage Type(s): Federal Government

Multiplan/Beech Street/PHCS

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

MVP

Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP

Non-Participating Plans with Out of Network Benefits

Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

Payor Type:
In Network Coverage Type(s): TBD

Oscar

Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO

Oxford

Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO

Qualcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Straight NJ Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Straight NY Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Tricare

Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO

UMR

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS

United Healthcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

World Trade Center Health Program (WTC)

Payor Type: Commercial
In Network Coverage Type(s): State Government

Contact and Location

Locations map
Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

MD, University of Mumbai

Residencies

Nuclear Medicine - Radiation Medicine Center/Tata Memorial Hospital; Internal Medicine - St. Luke's-Roosevelt Hospital Center/Columbia University

Fellowships

Hematology/Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine; Medical Oncology

 

I am a medical oncologist dedicated to caring for people with breast cancer. Each year, I provide care to approximately 300 people across Memorial Sloan Kettering Cancer Center (MSK) in Manhattan and the David H. Koch Center for Cancer Care. I am fortunate to have a career that I’m passionate about and that allows me to help so many people, both in the clinic and through research that may impact cancer care in the future.

Read more

When patients first meet with me, I take time to address their concerns about their diagnosis and answer their questions regarding treatment and prognosis. I try to lessen their anxiety and earn their trust so they feel comfortable in my presence. It is important to me that patients know they are in good hands with me, and with their experienced clinical care team, which includes a registered nurse, a nurse practitioner, or a physician assistant. When needed, I also refer patients to a social worker, a support group, and/or integrative medicine services. These resources can help patients cope and improve their overall wellbeing.

Some people may wonder if they did something wrong or are somehow responsible for developing cancer, but I reassure them that it is not their fault. Whether a person has early-stage disease or their cancer has metastasized (spread), I help them focus on what we can do and encourage them with information about research developments and new treatment options that may benefit them. We talk about exciting advances in the field that have led to our ability to cure patients, achieve long-term remissions, and prolong survival while maintaining quality of life, even for those with late-stage disease. In instances when patients are not able to receive treatment or do not wish to pursue therapy, I help them navigate those decisions.

Medical oncology is a unique subspecialty because it allows doctors and patients to cultivate close relationships and, in most cases, requires continuity of care. I chose this field not only because I wanted to understand the science and biology behind what drives cancer while working to find a cure or ways to improve patient outcomes, but also to develop long-term relationships with patients and their families. Patients let me into the most intimate aspects of their lives; I am privileged to be able to celebrate their happy moments and, in other instances, to guide them and their loved ones through very difficult times.

At MSK, I conduct translational research in collaboration with my laboratory colleagues to shepherd our findings from the lab to the clinic. Through my research, I aim to accelerate the development of new treatments and improve outcomes for people with breast cancer. Our latest work involves the use of acquired biospecimen (cell-free DNA and tumor) analyses and imaging studies to identify and understand biomarkers indicating response or resistance to breast cancer treatment.

As the section head for the Endocrine Therapy Research Program, I manage the clinical trial portfolio for hormone receptor-positive HER2-negative/low breast cancer. I am currently involved with trials evaluating novel PI3K inhibitors, new endocrine drugs used alone or in combination with other drugs, and antibody drug conjugates, among other investigational therapies. I also serve as the Clinical Director for the Early Drug Development Service. This work positions me as the principal investigator for many exciting phase 1 trials led by this service.

Outside of work, I enjoy traveling and playing board games with my family. I also like to relax by participating in my book club and stay active by skiing, dancing, and playing tennis.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Breast Medicine Service doctors

See all Early Drug Development Service doctors

Clinical Trials

Research and Publications

Jhaveri K, Juric D, Yap Y, Cresta S, Layman R, Duhoux F, Terret C, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, Curigliano G. A phase 1 study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib in patients with estrogen receptor-positive breast cancer. Clin Cancer Res. 2021;27(21):5760-70. PMID: 34433648         

Jhaveri K, Drago J, Shah P, Wang R, Pareja F, Ratzon F, Iasonos A, Patil S, Rosen N, Fornier M, Sklarin N, Chandarlapaty S, and Modi S A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer. Clin Cancer Res. 2021;27(14):3867-3875. PMID: 33947692

Jhaveri K, dos Anjos CH, Taldone T, Wang R, Comen E, Fornier M, Bromberg J, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy M, Modi S. Measuring tumor epichaperome expression using [124I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer. JCO Precision Oncology. 2020;4:PO.20.00273. PMCID: PMC7713524

Jhaveri K*, Wang XV, Makker V, Luoh S-W, Mitchell E-P, Zwiebel J-A, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT. Ado-trastuzumab emtansine (T-DM1) inpatients with HER2-amplifiedtumors excluding breast and gastric/gastroesophageal junction(GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann of Oncol. 2019;30(11):1821–30. PMCID: PMC6927318  

Jhaveri K, Chang M ,  Juric D,  Saura C,  Gambardella V, Melnyk A, Patel M, Ribrag V, Ma C,  Aljumaily R, Bedard P, Sachdev J, Dunn L, Won H, Bond J, Jones S, Savage H, Scaltriti M, Wilson T, Wei M, Hyman D. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Clin Cancer Res. 2020 Nov 4; clincanres.2657.2020

Publications on PubMed

Visit PubMed for a full listing of Dr. Jhaveri’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Komal Jhaveri discloses the following relationships and financial interests:

  • AstraZeneca
    Provision of Services
  • Blueprint Medicines
    Provision of Services
  • Genzyme
    Provision of Services
  • Intellisphere, LLC
    Provision of Services
  • Loxo Oncology
    Provision of Services
  • Medscape
    Provision of Services
  • Novartis Pharmaceuticals Corporation
    Provision of Services
  • OncLive
    Provision of Services
  • Pfizer, Inc.
    Provision of Services
  • Physicians' Education Resource
    Provision of Services
  • Plexus Communications
    Provision of Services
  • Rain Therapeutics Inc.
    Provision of Services
  • Roche
    Provision of Services

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures